UBS Group Reiterates CHF 90 Price Target for Novartis (VTX:NOVN)

UBS Group set a CHF 90 price target on Novartis (VTX:NOVN) in a report released on Tuesday, Borsen Zeitung reports. The firm currently has a neutral rating on the stock.

Several other research analysts have also recently commented on NOVN. Goldman Sachs Group set a CHF 105 price target on Novartis and gave the stock a buy rating in a research note on Monday. Barclays set a CHF 80 price target on Novartis and gave the stock a sell rating in a research note on Friday, July 19th. Deutsche Bank set a CHF 90 price target on Novartis and gave the stock a neutral rating in a research note on Friday, July 19th. Jefferies Financial Group set a CHF 95 price target on Novartis and gave the stock a buy rating in a research note on Thursday, May 16th. Finally, HSBC set a CHF 88 price target on Novartis and gave the stock a neutral rating in a research note on Monday, July 22nd. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and six have given a buy rating to the company. Novartis has a consensus rating of Hold and an average target price of CHF 89.71.

Novartis has a one year low of CHF 72.45 and a one year high of CHF 88.30.

Novartis Company Profile

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Featured Article: Key terms to understand channel trading

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.